Established in 2004, Regentis Biomaterials is a tissue repair company that is developing and commercializing innovative biodegradable hydrogels for the local repair of damaged cartilage and bone.
Our platform technology is a family of hydrogels called Gelrin™. These gels can be injected or applied to a specific local site and offer beneficial properties for the local repair of damaged tissue such as cartilage and bone.
The Gelrin™ technology offers off-the-shelf products that are designed to be suitable for both open surgery and minimally invasive procedures. An ideal solution for physicians and their patients, the products are easy to implant and have been shown to stimulate the regeneration of healthy cartilage and bone tissue.
Regentis’ first orthopedic product is GelrinC, a biodegradable hydrogel for articular cartilage regeneration. Additional pipeline products include GelrinB - a biodegradable hydrogel for bone regeneration; and GelrinA - a void filling matrix for aesthetic indications.
Our Vision
Our vision is to develop tissue repair therapies that will provide patients with better treatment options for faster healing, and quicker recovery.
Caution: Investigational Device. Limited by U.S. law to investigational use. | 
